Next Article in Journal
Medication Trials for Hyperphagia and Food-Related Behaviors in Prader–Willi Syndrome
Next Article in Special Issue
Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent
Previous Article in Journal
Growth Hormone Therapy in Adults with Prader-Willi Syndrome
Previous Article in Special Issue
A Role for Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Therapeutic Strategy Targeting Phosphorylated Retinoid X Receptor-α
Article Menu

Export Article

Open AccessArticle
Diseases 2015, 3(2), 68-77;

Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Department of Internal Medicine, Hepatology Division, Saga University Hospital, 5-1-1 Nabeshima, Saga 849-8501, Japan
Department of Internal Medicine, Saiseikai Karatsu Hospital, 817 Motohata-machi, Karatsu 847-0852, Japan
Department of Internal Medicine, Gastroenterology Division, NHO Ureshino Medical Center, 2436 Shimojuku-hei Ureshino-machi, Ureshino 843-0393, Japan
Department of Internal Medicine, Karatsu Red Cross Hospital, 1-5-1 Futago, Karatsu 847-8588, Japan
Department of Hepatobiliary and Pancreatology, Saga-Ken Medical Centre Koseikan, 400 Nakabaru, Kase-machi, Saga 840-8571, Japan
Liver center, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
Members of the Saga Liver Cancer Study Group. The Saga Liver Cancer Study Group is composed of tertiary-care hospitals with specialists in liver cancer treatment in Saga Prefecture, Japan.
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Received: 26 March 2015 / Revised: 19 April 2015 / Accepted: 6 May 2015 / Published: 15 May 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Full-Text   |   PDF [776 KB, uploaded 15 May 2015]   |  


Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed post-progression survival (PPS) using the Cox proportional hazards model. PPS was calculated from the date of the first rPD until the date of death or the last follow-up. Using Cox model analysis of the 76 patients who experienced first rPD, we identified the Child-Pugh class, Eastern Cooperative Oncology Group performance status, the best antitumor response during treatment (using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1) and α-fetoprotein levels as independent factors affecting PPS. When these factors were used to define scores ranging from zero to five with a cutoff value of two, PPS of patients who received best supportive care (BSC) after rPD was not statistically significantly different from that of patients who received post-rPD therapy with scores ≥2 (p = 0.220). In contrast, the PPS for the post-rPD therapy group was significantly longer compared with the BSC patients with scores <2 (p < 0.001). Patients who scored ≥2 at their first rPD were judged cPD and as candidates for BSC. View Full-Text
Keywords: beyond progression; progressive disease; scoring system; post-progression survival beyond progression; progressive disease; scoring system; post-progression survival

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Otsuka, T.; Nakashita, S.; Yanagita, K.; Ario, K.; Kawasoe, H.; Kawazoe, S.; Eguchi, Y.; Mizuta, T. Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases 2015, 3, 68-77.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top